Sign in to view content

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Vrinda S. Hershberger, MD, PhD

Video
Published 2021

Related

Episode 25: RIVAL Study: Ranibizumab vs Aflibercept in T&E for wet AMD with Dr. Mark Gillies
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019
Episode 23: CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD with Dr. Peter Kertes
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019
Phase 1 Safety Study of Intravitreal (ITV) Anti-High Temperature Requirement A1 (aHtrA1), a Novel Serine Protease Inhibitor, in Patients With GA
William Z. Bridges, MD
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more